<a href="https://www.fiercebiotech.com/biotech/astellas-pharma-and-dyno-therapeutics-unearth-15m-muscle-disorder-capsid-ongoing" hreflang="en">Astellas unearths Dyno muscle disorder AAV capsid with $15M option agreement</a>
fiercebiotech.com·Apr 7, 2026
Astellas Pharma has licensed a gene therapy vehicle from Dyno Therapeutics, an adeno-associated virus capsid designed for delivering treatments to skeletal muscle, following their research collaboration initiated in 2021.
Astellas Pharma's licensing of Dyno Therapeutics' engineered AAV capsid highlights the growing trend and opportunity in leveraging advanced gene therapy vehicles for targeted therapeutic delivery, particularly in skeletal muscle applications. For professionals in healthtech and biotech, this signifies a strategic area for investment and innovation, as engineered viral vectors continue to advance precision medicine capabilities.